>中东和非洲遗传性视网膜疾病市场，按疾病类型（视网膜色素变性、斯塔加特病、全色盲、视锥杆营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等）、按类型（诊断和治疗）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（零售销售和直接招标）划分，行业趋势及预测至 2029 年。
市场分析和见解：中东和非洲遗传性视网膜疾病市场
遗传性视网膜疾病（IRD）是一组可能导致严重视力丧失甚至失明的疾病。每个 IRD 都由至少一个基因无法正常工作引起。IRD 会影响所有年龄段的人，进展速度不同，而且很少见。然而，许多 IRD 是退行性的，这意味着疾病的症状会随着时间的推移而恶化。常见的 IRD 类型包括莱伯先天性黑蒙 (LCA)、视网膜色素变性、脉络膜白斑、斯塔加特病和全色盲。基因治疗的目标是纠正或补偿有缺陷的基因。由于视网膜具有独特的物理构造，IRD 是基因治疗的强有力候选者。与身体的其他器官相比，眼睛很小，易于进行治疗。然而，身体的某些部位具有免疫特权，这意味着正常的免疫反应不那么活跃。这通常发生在我们身体非常重要的部位，如果出现肿胀或炎症，可能会受损。这意味着植入眼睛的任何东西（例如带有修正基因的细胞）都不太可能被排斥。
遗传性视网膜疾病的诊断和治疗包括各种技术，这些技术允许在产品获批后诊断遗传性视网膜疾病。该疾病的治疗方法最近获得批准，这支持了市场的增长。
遗传性视网膜疾病具有支持作用，旨在减少疾病的进展。Data Bridge Market Research 分析，遗传性视网膜疾病市场在 2022 年至 2029 年的预测期内将以 5.7% 的复合年增长率增长。
|
报告指标 |
细节 |
|
预测期 |
2022 至 2029 年 |
|
基准年 |
2021 |
|
历史岁月 |
2020（可定制至 2019 - 2014） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
疾病类型（视网膜色素变性、斯塔加特病、全色盲、视锥细胞-视杆细胞营养不良、脉络膜缺失、莱伯先天性黑蒙、黄斑水肿等）、按类型（诊断和治疗）、最终用户（医院、专科诊所、门诊手术中心、家庭医疗保健等）、分销渠道（零售和直接招标） |
|
覆盖国家 |
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) |
|
Market Players Covered |
Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies |
Inherited Retinal Diseases Market Dynamics
Drivers
- Increase in the Prevalence of Inherited Retinal Diseases
The increasing prevalence and continuous discovery of new mutagenic sites that are genetically transmitted are expected to act as a driver for the growth of the market. The prevalence of monogenic IRDs is approximately 1 in 2000 affecting two million people online.
- Increasing in Pipeline Products
As clinical trial activity rises to new levels, the field appears poised to make rapid and important advances in IRD research and patient care. These are only a few common trials, thus, the companies operating in this market continuously do clinical trials and put their candidates in clinical trials. This is expected to create an opportunity and fuel the Middle East and Africa inherited retinal diseases market.High prevalence of genetic conditions
Also, the increase in the prevalence rate of some genetic conditions such as Miller-Dieker syndrome and Walker-Warburg syndrome will further enhance the growth of inherited retinal diseases market.
Furthermore, Increase in strategic initiatives by key players, advancement in medical technology, increasing product approval for IRDs, rising initiatives by public and private organizations to spread awareness and growing government funding are the factors that will expand the inherited retinal diseases market. Other factors such as increase in the demand for effective therapies and rising adoption rate for early genetic counseling will positively impact the inherited retinal diseases market's growth rate. Additionally, high disposable income, rising number of cases of various retinal diseases will result in the expansion of inherited retinal diseases market.
Opportunities
- Increase in Government Initiatives Towards Inherited Retinal Disease.
Moreover, the increase in awareness and treatment seeking rate and emerging reimbursement policies for the treatment will boost new opportunities for the market's growth rate.
Also, the launch of effective therapies and continuous clinical trials will provide beneficial opportunities for the inherited retinal diseases market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate inherited retinal diseases market in future.
Restraints/Challenges
However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of inherited retinal diseases market. Additionally, lack of enough qualified professionals, and complications involved with the disease will hinder the inherited retinal diseases market growth.
This inherited retinal diseases market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Inherited retinal diseases market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Patient Epidemiology Analysis
Inherited retinal disease is a genetic disorder that is relatively uncommon and whose incidence is unknown. According to a study of inherited retinal diseases the prevalence of IRD’s is 1 in 3000.
Retinitis pigmentosa is the most common disorder among the other disorders. Retinitis pigmentosa is a group of related eye disorders caused by variations in 60 genes that affect the retina. IRDs are a heterogeneous group of orphan eye diseases with a prevalence estimated at between 0.5% and 0.1%, with a Middle East and Africa IRD caseload in the range of 50,000 individuals.
Inherited retinal diseases market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Post COVID-19 Impact on Inherited Retinal Diseases Market
The COVID-19 has negatively affected the market. Lockdowns and isolation during pandemics complicate the disease management and medication adherence. The lack of access to health-care facilities for routine treatment and medication administration will further affect the market. Social isolation increases stress, despair, and social support, all of which may cause a reduction in anticonvulsant medication adherence during the pandemic.
Recent Development
- In December 2021,, the Middle East Contries such as Saudi Arabia among others have approved the Luxturna therapy.
Middle East and Africa Inherited Retinal Diseases Market Scope
The inherited retinal diseases market is segmented into disease type, type, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Disease Type
- Retinitis Pigmentosa
- Stargardt’s Disease
- Achromatopsia
- Cone-Rod Dystrophy
- Choroideremia
- Leber Congenital Amaurosis (LCA)
- Macular Edema
- Others
On the basis of type, the inherited retinal diseases market is segmented into disease type (retinitis pigmentosa, stargardt’s disease, achromatopsia, cone-rod dystrophy, choroideremia, leber congenital amaurosis, macular edema, and others), by type (diagnosis and therapy), end-users (hospitals, specialty clinics, ambulatory surgical centers, home healthcare, others), distribution channel (retail sales and direct tender.
Type
- Diagnosis
- Therapy
On the basis of type, the inherited retinal diseases market is segmented into diagnosis and therapy. The diagnosis segment is sub-segmented into gene therapy, retinal prosthetic, neuroprotective agents, others. The neuroprotective agents are further sub-segmented into vitamin A palmitate, docosahexaenoic acid (DHA), lutein, others. The diagnosis segment is segmented into clinical diagnosis and genetic diagnosis. Clinical diagnosis is further sub-segmented into retinal imaging, electrophysiological tests, visual field test and clinical eye examination. Retinal imaging is further segmented into optical coherence tomography (OCT), fundus autofluorescence imaging (FAF), scanning laser ophthalmoscopy (SLO), adaptive optics (AO) imaging and conventional color fundus imaging. Electrophysiological tests are further segmented into full-field electroretinogram (ERG) and dark adaptometry (DA). Visual field test is further segmented into computerized visual field tests and manual field test. Clinical Eye examination is segmented into slit lamp, indirect ophthalmoscopy, refraction test, dilation exam
End User
- Hospitals
- Specialty Clinics
- Ambulatory surgical center
- Home Healthcare
- Others
On the basis of end-users, the inherited retinal diseases market is segmented into hopsitals, specialty clinics, ambulatory surgical center, home healthcare and others
Distribution Channel
- Retail Sales
- Direct Tender
The inherited retinal diseases market is also segmented on the basis of distribution channel into retail sales, direct tender.
Pipeline Analysis
The pipeline analysis of inherited retinal diseases drugs includes various pipeline therapies such as NCT05244304, NCT00999609, NCT05176717, NCT05158296, NCT04850118. Belite Bio, Inc, Spark Therapeutics, ProQR Therapeutics, Applied Genetic Technologies Corp, Biogen, MeiraGTx Ltd are involved in the development of potential drugs for the improvement of treatment of seizures.
Inherited Retinal Diseases Market Regional Analysis/Insights
The inherited retinal diseases market is analysed and market size insights and trends are provided by country, disease type, type, end-user and distribution channel as referenced above.
The countries covered in the inherited retinal diseases market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA).
Saudi Arabia dominates the inherited retinal diseases market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and well-developed healthcare infrastructure in this region.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Middle East and Africa brands and their challenges faced due to high competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Inherited Retinal Diseases Market Share Analysis
The inherited retinal diseases market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Middle East and Africa presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus on inherited retinal diseases market.
Some of the major players operating in the inherited retinal diseases market are Spark Therapeutics, Novartis AG, Okuvision, Nidek Co. Ltd., Invitae Corporation, Carl Zeiss Meditech AG, Optos (A Subdidiary of Nikon Corporation, Neurosoft, PIXIUM VISION, LKC TECHNOLOGIES, INC., Renurone, Astellas Pharma, REGENXBIO Inc., Ionis Pharmaceutics, Sparing Vision, Ocugen Inc, Johnson & Johnson, IVERIC bio, Second Sight, Coave Therapeutics, MeiraGTx Limited, Gensight Biologics, ProQR Therapeutics, Bionic Vision Technologies among others.
Research Methodology: Middle East and Africa Inherited Retinal Diseases Market
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。DBMR 研究团队使用的关键研究方法是数据三角测量，涉及数据挖掘、数据变量对市场影响的分析以及主要（行业专家）验证。除此之外，数据模型还包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、公司市场份额分析、测量标准、中东和非洲与地区和供应商份额分析。如有进一步询问，请要求分析师致电。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PIPELINE ANALYSIS FOR MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET
5 REGULATORY FRAMEWORK
6 PREMIUM INSIGHTS
6.1 PESTEL ANALYSIS
6.2 POTER’S FIVE FORCES MODEL
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES
7.1.2 INCREASE IN PIPELINE PRODUCTS
7.1.3 INCREASING PRODUCT APPROVAL FOR INHERITED RETINAL DISEASES
7.1.4 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER
7.2 RESTRAINTS
7.2.1 HIGH COST OF TREATMENT AND PROCEDURES
7.2.2 LACK OF ENOUGH QUALIFIED PROFESSIONALS
7.3 OPPORTUNITIES
7.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARDS INHERITED RETINAL DISEASES(IRDS)
7.3.2 INCREASE IN AWARENESS AND TREATMENT-SEEKING RATE
7.3.3 EMERGING REIMBURSEMENT POLICIES FOR THE TREATMENT
7.4 CHALLENGES
7.4.1 RISKS ASSOCIATED WITH IRD SPECIFIC GENE THERAPY
7.4.2 LIMITED ACCESS TO TREATMENT
8 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE
8.1 OVERVIEW
8.2 RETINITIS PIGMENTOSA
8.3 STARGARDT’S DISEASE
8.4 ACHROMATOPSIA
8.5 CONE-ROD DYSTROPHY
8.6 CHOROIDEREMIA
8.7 LEBER CONGENITAL AMAUROSIS (LCA)
8.8 MACULAR EDEMA
8.9 OTHERS
9 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE
9.1 OVERVIEW
9.2 DIAGNOSIS
9.2.1 CLINICAL DIAGNOSIS
9.2.1.1 RETINAL IMAGING
9.2.1.1.1 OPTICAL COHERENCE TOMOGRAPHY (OCT)
9.2.1.1.2 FUNDUS AUTOFLUORESCENCE IMAGING (FAF)
9.2.1.1.3 SCANNING LASER OPHTHALMOSCOPY (SLO)
9.2.1.1.4 ADAPTIVE OPTICS (AO) IMAGING
9.2.1.1.5 CONVENTIONAL COLOR FUNDUS IMAGING
9.2.1.2 ELECTROPHYSIOLOGICAL TESTS
9.2.1.2.1 FULL-FIELD ELECTRORETINOGRAM (ERG)
9.2.1.2.2 DARK ADAPTOMETRY (DA)
9.2.1.3 VISUAL FIELD TEST
9.2.1.3.1 COMPUTERIZED VISUAL FIELD TESTS
9.2.1.3.2 MANUAL FIELD TEST
9.2.1.4 CLINICAL EYE EXAMINATION
9.2.1.4.1 SLIT LAMP
9.2.1.4.2 INDIRECT OPHTHALMOSCOPY
9.2.1.4.3 REFRACTION TEST
9.2.1.4.4 DILATION EXAM
9.2.1.5 OTHERS
9.2.2 GENETIC DIAGNOSIS
9.3 THERAPY
9.3.1 GENE THERAPY
9.3.2 RETINAL PROSTHETIC
9.3.3 NEUROPROTECTIVE AGENTS
9.3.3.1 VITAMIN A PALMITATE
9.3.3.2 DOCOSAHEXAENOIC ACID
9.3.3.3 LUTEIN
9.3.3.4 OTHERS
9.3.4 OTHERS
10 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 SPECIALTY CLINICS
10.4 AMBULATORY SURGICAL CENTERS
10.5 HOME HEALTHCARE
10.6 OTHERS
11 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL
11.1 OVERVIEW
11.2 RETAIL SALES
11.2.1 HOSPITAL PHARMACIES
11.2.2 RETAIL PHARMACIES
11.2.3 OTHERS
11.3 DIRECT TENDER
12 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY REGION
12.1 MIDDLE EAST & AFRICA
12.1.1 SOUTH AFRICA
12.1.2 SAUDI ARABIA
12.1.3 U.A.E.
12.1.4 ISRAEL
12.1.5 EGYPT
12.1.6 KUWAIT
12.1.7 REST OF MIDDLE EAST & AFRICA
13 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: COMPANY LANDSCAPE
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
14 SWOT ANALYSIS
15 COMPANY PROFILE
15.1 SPARK THERAPEUTICS, INC.
15.1.1 COMPANY SNAPSHOT
15.1.2 COMPANY SHARE ANALYSIS
15.1.3 PRODUCT PORTFOLIO
15.1.4 RECENT DEVELOPMENTS
15.1.4.1 PROGRAM LAUNCH
15.1.4.2 ACQUISITIONS
15.2 NOVARTIS AG
15.2.1 COMPANY SNAPSHOT
15.2.2 REVENUE ANALYSIS
15.2.3 COMPANY SHARE ANALYSIS
15.2.4 PRODUCT PORTFOLIO
15.2.5 RECENT DEVELOPMENT
15.2.5.1 AGREEMENT
15.3 OKUVISION
15.3.1 COMPANY SNAPSHOT
15.3.2 COMPANY SHARE ANALYSIS
15.3.3 PRODUCT PORTFOLIO
15.3.4 RECENT DEVELOPMENTS
15.3.4.1 EXPANSION
15.3.4.2 EVENTS
15.3.4.3 APPROVAL
15.4 NIDEK CO., LTD
15.4.1 COMPANY SNAPSHOT
15.4.2 COMPANY SHARE ANALYSIS
15.4.3 PRODUCT PORTFOLIO
15.4.4 RECENT DEVELOPMENTS
15.4.4.1 PRODUCT LAUNCH
15.4.4.2 PRODUCT LAUNCH
15.5 INVITAE CORPORATION
15.5.1 COMPANY SNAPSHOT
15.5.2 REVENUE ANALYSIS
15.5.3 COMPANY SHARE ANALYSIS
15.5.4 PRODUCT PORTFOLIO
15.5.5 RECENT DEVELOPMENTS
15.5.5.1 PROGRAM LAUNCH
15.5.5.2 ACQUISITION
15.6 ZEISS INTERNATIONAL
15.6.1 COMPANY SNAPSHOT
15.6.2 REVENUE ANALYSIS
15.6.3 PRODUCT PORTFOLIO
15.6.4 RECENT DEVELOPMENTS
15.6.4.1 EVENTS
15.6.4.2 SOCIAL INVOLVEMENT
15.7 OPTOS (A SUBSIDIARY OF NIKON CORPORATION)
15.7.1 COMPANY SNAPSHOT
15.7.2 REVENUE ANALYSIS
15.7.3 PRODUCT PORTFOLIO
15.7.4 RECENT DEVELOPMENTS
15.8 NEUROSOFT
15.8.1 COMPANY SNAPSHOT
15.8.2 PRODUCT PORTFOLIO
15.8.3 RECENT DEVELOPMENTS
15.9 ASTELLAS PHARMA INC.
15.9.1 COMPANY SNAPSHOT
15.9.2 REVENUE ANALYSIS
15.9.3 PRODUCT PORTFOLIO
15.9.4 RECENT DEVELOPMENTS
15.1 BIONIC VISION TECHNOLOGIES
15.10.1 COMPANY SNAPSHOT
15.10.2 PRODUCT PORTFOLIO
15.10.3 RECENT DEVELOPMENT
15.10.3.1 AWARD
15.11 COAVE THERAPEUTICS
15.11.1 COMPANY SNAPSHOT
15.11.2 PRODUCT PORTFOLIO
15.11.3 RECENT DEVELOPMENT
15.11.3.1 AGREEMENT
15.12 GENSIGHT BIOLOGICS
15.12.1 COMPANY SNAPSHOT
15.12.2 REVENUE ANALYSIS
15.12.3 PRODUCT PORTFOLIO
15.12.4 RECENT DEVELOPMENTS
15.12.4.1 EVENT
15.12.4.2 AWARD
15.13 IONIS PHARMACEUTICALS
15.13.1 COMPANY SNAPSHOT
15.13.2 REVENUE ANALYSIS
15.13.3 PRODUCT PORTFOLIO
15.13.4 RECENT DEVELOPMENT
15.13.4.1 EVENT
15.14 IVERIC BIO
15.14.1 COMPANY SNAPSHOT
15.14.2 PRODUCT PORTFOLIO
15.14.3 RECENT DEVELOPMENTS
15.15 JOHNSON &JOHNSON SERVICES, INC.
15.15.1 COMPANY SNAPSHOT
15.15.2 REVENUE ANALYSIS
15.15.3 PRODUCT PORTFOLIO
15.15.4 RECENT DEVELOPMENT
15.15.4.1 COLLABORATION
15.16 LKC TECHNOLOGIES, INC.
15.16.1 COMPANY SNAPSHOT
15.16.2 PRODUCT PORTFOLIO
15.16.3 RECENT DEVELOPMENT
15.16.3.1 PRODUCT LAUNCH
15.17 MEIRAGTX LIMITED
15.17.1 COMPANY SNAPSHOT
15.17.2 PRODUCT PORTFOLIO
15.17.3 RECENT DEVELOPMENTS
15.17.3.1 EVENTS
15.17.3.2 AWARD
15.17.3.3 COLLABORATION
15.18 OCUGEN INC.
15.18.1 COMPANY SNAPSHOT
15.18.2 PRODUCT PORTFOLIO
15.18.3 RECENT DEVELOPMENTS
15.18.3.1 INVESTMENT
15.18.3.2 CLINICAL TRIAL
15.19 PIXIUM VISION
15.19.1 COMPANY SNAPSHOT
15.19.2 REVENUE ANALYSIS
15.19.3 PRODUCT PORTFOLIO
15.19.4 RECENT DEVELOPMENT
15.19.4.1 AWARD
15.2 PROQR THERAPEUTICS
15.20.1 COMPANY SNAPSHOT
15.20.2 PRODUCT PORTFOLIO
15.20.3 RECENT DEVELOPMENT
15.20.3.1 EVENT
15.21 SECOND SIGHT
15.21.1 COMPANY SNAPSHOT
15.21.2 PRODUCT PORTFOLIO
15.21.3 RECENT DEVELOPMENT
15.21.3.1 PRODUCT LAUNCH
15.22 SPARING VISION
15.22.1 COMPANY SNAPSHOT
15.22.2 PRODUCT PORTFOLIO
15.22.3 RECENT DEVELOPMENT
15.22.3.1 ACQUISITION
15.23 REGENXBIO INC.
15.23.1 COMPANY SNAPSHOT
15.23.2 PRODUCT PORTFOLIO
15.23.3 RECENT DEVELOPMENTS
15.23.3.1 EVENT
15.23.3.2 COLLABORATION
15.23.3.3 CERTIFICATION
15.24 RENEURON GROUP PLC
15.24.1 COMPANY SNAPSHOT
15.24.2 PRODUCT PORTFOLIO
15.24.3 RECENT DEVELOPMENT
15.24.3.1 STRATEGIC INITIATIVE
16 QUESTIONNAIRE
17 RELATED REPORTS
表格列表
TABLE 1 PIPELINE ANALYSIS FOR INHERITED RETINAL DISEASES:
TABLE 2 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA RETINITIS PIGMENTOSA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA STARGARDT’S DISEASE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA ACHROMATOPSIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA CONE-ROD DYSTROPHY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA CHOROIDERMIA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA LEBER CONGENITAL AMAUROSIS (LCA) IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA MACULAR EDEMA IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TETS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA HOSPITALS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA SPECIALTY CLINICS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA AMBULATORY SURGICAL CENTERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA HOME HEALTHCARE IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA OTHERS IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA DIRECT TENDER IN INHERITED RETINAL DISEASES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 46 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 47 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 48 SOUTH AFRICA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 SOUTH AFRICA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 50 SOUTH AFRICA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 51 SOUTH AFRICA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 52 SOUTH AFRICA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 53 SOUTH AFRICA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 54 SOUTH AFRICA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 55 SOUTH AFRICA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 57 SOUTH AFRICA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 58 SOUTH AFRICA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 59 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 60 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 61 SAUDI ARABIA THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 62 SAUDI ARABIA NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 63 SAUDI ARABIA DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 SAUDI ARABIA CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 65 SAUDI ARABIA RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 66 SAUDI ARABIA ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 67 SAUDI ARABIA VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 68 SAUDI ARABIA CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 69 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 70 SAUDI ARABIA INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 71 SAUDI ARABIA RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 72 U.A.E. INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 73 U.A.E. INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.A.E. THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 75 U.A.E. NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 76 U.A.E. DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 77 U.A.E. CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.A.E. RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 79 U.A.E. ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 80 U.A.E. VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.A.E. CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 82 U.A.E. INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 83 U.A.E. INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 84 U.A.E. RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 85 ISRAEL INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 86 ISRAEL INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 87 ISRAEL THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 88 ISRAEL NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 ISRAEL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 90 ISRAEL CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 91 ISRAEL RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 92 ISRAEL ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 ISRAEL VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 94 ISRAEL CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 95 ISRAEL INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 96 ISRAEL INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 ISRAEL RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 98 EGYPT INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 99 EGYPT INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 100 EGYPT THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 101 EGYPT NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 102 EGYPT DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 103 EGYPT CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 104 EGYPT RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 105 EGYPT ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 106 EGYPT VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 EGYPT CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 108 EGYPT INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 109 EGYPT INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 110 EGYPT RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 111 KUWAIT INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
TABLE 112 KUWAIT INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 113 KUWAIT THERAPY IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 KUWAIT NEUROPROTECTIVE AGENTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 115 KUWAIT DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 116 KUWAIT CLINICAL DIAGNOSIS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 117 KUWAIT RETINAL IMAGING IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 KUWAIT ELECTROPHYSIOLOGICAL TESTS IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 119 KUWAIT VISUAL FIELD TEST IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 120 KUWAIT CLINICAL EYE EXAMINATION IN INHERITED RETINAL DISEASES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 121 KUWAIT INHERITED RETINAL DISEASES MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 122 KUWAIT INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 123 KUWAIT RETAIL SALES IN INHERITED RETINAL DISEASES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 124 REST OF MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: VENDOR SHARE ANALYSIS
FIGURE 11 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: SEGMENTATION
FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE AND EUROPE IS GROWING AT THE FASTEST PACE IN MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 13 INCREASE IN THE PREVALENCE OF INHERITED RETINAL DISEASES AND INCREASE IN PIPELINE PRODUCTS ARE DRIVING THE MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 14 RETINITIS PIGMENTOSA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET IN 2022 & 2029
FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET
FIGURE 16 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2021
FIGURE 17 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, 2020-2029 (USD MILLION)
FIGURE 18 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, CAGR (2022-2029)
FIGURE 19 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2021
FIGURE 21 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2021
FIGURE 25 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 26 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY END USER, CAGR (2022-2029)
FIGURE 27 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 29 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 30 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 31 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: SNAPSHOT (2021)
FIGURE 33 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021)
FIGURE 34 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 35 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 36 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: BY DISEASE TYPE (2022-2029)
FIGURE 37 MIDDLE EAST & AFRICA INHERITED RETINAL DISEASES MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
